Institute of Regenerative and Cellular Medicine – FDA 483, Oct 19, 2021
An FDA inspection of the Institute of Regenerative and Cellular Medicine in Santa Monica, CA, revealed significant deficiencies in its Institutional Review Board (IRB) operations. The firm failed to maintain complete records of continuing review activities, did not follow its own written procedures for informing Principal Investigators (PIs) of IRB actions, and lacked sufficiently detailed meeting minutes for controverted issues and resolutions. Furthermore, the IRB reviewed drug studies for which it was not registered, indicating a systemic failure in regulatory compliance and oversight of clinical trials.
- Inspection date
- October 19, 2021
- Product type
- biologics
ID · 89e533f2-e930-489c-855b-16bf5684d476
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.